EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Natural Bioactive Compounds Targeting Lipid Metabolism in Metabolic Dysfunction‐Associated Steatotic Liver Disease

Ji-Kai Ma, Jian-Fei Yang, Yu-Ping Ma, Bing-Qiang Chen, Sheng-Cai Li iD, Yu-Bei Lu, Zhong Xu, Yan-Long Li

Phytotherapy Research · 13.11.2026

DOI: 10.1002/ptr.70525 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Phytotherapy Research, online erschienen am 13.11.2026. Verfasst von Ji-Kai Ma und 7 weiteren Autor:innen. Beteiligte Einrichtung: Gansu University of Chinese Medicine, Lanzhou, China. Die Arbeit nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Gansu Provincial Administration of Traditional Chinese Medicine, Construction Fund for Famous Traditional Chinese Medicine Practitioner Studios of Gansu Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction‐associated steatotic liver disease (MASLD) is a common chronic liver disease worldwide, with abnormal lipid accumulation in hepatocytes as its principal pathological alteration. Disruption of hepatic lipid homeostasis is associated with processes such as fatty acid uptake, de novo lipogenesis (DNL), fatty acid oxidation (FAO), lipid transport, and autophagy–lipophagy‐mediated clearance, and it drives the onset and progression of MASLD. Although some drugs have been approved for patients with specific metabolic dysfunction‐associated steatohepatitis (MASH) and moderate‐to‐severe fibrosis, therapeutic options that are broadly applicable across the full MASLD disease spectrum, particularly for patients with early steatosis, complex metabolic phenotypes, and multiple coexisting metabolic abnormalities, remain limited in terms of population coverage, long‐term safety, and clearly defined therapeutic targets. In this article, relevant databases, including PubMed and the Web of Science Core Collection, were searched to include basic experimental and clinical studies related to lipid metabolism dysregulation and intervention with natural bioactive compounds within the MASLD/MASH disease spectrum, and the findings were organized according to molecular processes and clinical applications. The available evidence suggests that natural bioactive compounds may modulate hepatic lipid homeostasis by reducing fatty acid uptake and de novo lipogenesis, enhancing fatty acid oxidation, regulating lipid transport and export‐related pathways, restoring autophagy–lipophagy‐mediated lipid droplet clearance, and attenuating gut–liver axis dysregulation, oxidative stress, and inflammatory injury. From the perspective of lipid metabolism, this article summarizes the molecular processes, clinical evidence, and application barriers associated with natural bioactive compounds in the intervention of MASLD, with the aim of providing a basis for subsequent research on the prevention and treatment of MASLD using natural products.

Schlagwörter

Stichwörter der Autor:innen

autophagy‐lipophagyde novo lipogenesislipid metabolismmetabolic dysfunction‐associated steatotic liver diseasenatural bioactive compounds

Autor:innen und Institutionen

  • Gansu University of Chinese Medicine, Lanzhou, China.
  • Gansu Provincial Hospital of Traditional Chinese Medicine, Lanzhou, China.

ORCID-Profile: Sheng-Cai Li

Förderung

  • National Natural Science Foundation of China
  • Gansu Provincial Administration of Traditional Chinese Medicine
  • Construction Fund for Famous Traditional Chinese Medicine Practitioner Studios of Gansu Province

Zitieren

APA

Ma, J. K., Yang, J. F., Ma, Y. P., Chen, B. Q., Li, S. C., Lu, Y. B., Xu, Z., & Li, Y. L. (2026). Natural Bioactive Compounds Targeting Lipid Metabolism in Metabolic Dysfunction‐Associated Steatotic Liver Disease. Phytotherapy Research. https://doi.org/10.1002/ptr.70525

Vancouver

Ma JK, Yang JF, Ma YP, Chen BQ, Li SC, Lu YB, et al. Natural Bioactive Compounds Targeting Lipid Metabolism in Metabolic Dysfunction‐Associated Steatotic Liver Disease. Phytotherapy Research. 2026. doi:10.1002/ptr.70525

BibTeX
@article{Ma2026,
  author = {Ma, Ji-Kai and Yang, Jian-Fei and Ma, Yu-Ping and Chen, Bing-Qiang and Li, Sheng-Cai and Lu, Yu-Bei and Xu, Zhong and Li, Yan-Long},
  title = {Natural Bioactive Compounds Targeting Lipid Metabolism in Metabolic Dysfunction‐Associated Steatotic Liver Disease},
  journal = {Phytotherapy Research},
  year = {2026},
  doi = {10.1002/ptr.70525}
}
Kostenlos starten →